Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
OTC Drugs

Pre-emption Limits Survive Congress, But Will Face Supreme Court

This article was originally published in The Tan Sheet

  • News

Executive Summary

The FDA reauthorization law signed by President Bush Sept. 27 includes provisions intended to sustain limits on federal pre-emption, but the concept is challenged in several ongoing cases that could reach the Supreme Court in coming sessions
Table

View full table

Advertisement

Related Content

Pink Sheet
FDA’s Chief Scientist Has Full Plate To Concentrate On: Clinical Research
HBW Insight
FDA’s Chief Scientist Has Full Plate To Concentrate On: Clinical Research
Pink Sheet
FDA Stymied By Reauthorization Terms That May Slow Ingredient Development
Pink Sheet
FDA Stymied By Reauthorization Terms That May Slow Ingredient Development
HBW Insight
FDA Stymied By Reauthorization Terms That May Slow Ingredient Development
Pink Sheet
FDA’s Drug Safety Office Reorganizing To Accommodate Influx Of PDUFA Staff
Pink Sheet
FDA Preemption: Proposed Labeling Rule Draws Opposition From All Sides
Pink Sheet
FDA Amendments Act Of 2007 By Any Other Name Would Be Preferred
Pink Sheet
Pre-emption in High Court
Pink Sheet
FDA seeks foundation board members

Topics

Advertisement
Tags:
OTC Drugs
UsernamePublicRestriction

Register

PS100959

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By